Assess Genomic Integrity With Optical Genome Mapping

Cell and gene therapies (CGT) mark a transformative phase in medical innovation, with the FDA endorsing 32 treatments by 2023 and over 1,000 CGTs currently in U.S. clinical trials, alongside 3,000 in preclinical phases. While these therapies hold immense potential in disease management, ensuring their integrity is crucial. Challenges like mutations from genetic editing and extended culture growth pose risks to CGTs' safety and efficacy. Conventional genomic analysis methods often fall short in detecting critical structural variants. In this webinar, you’ll discover how to evaluate cell and gene therapy genetic integrity and purity with optical genome mapping (OGM). Best practice guidance Attend this webinar to: • Explore the evolving landscape of CGT and the imperative of ensuring therapeutic safety Best practice guidance • Gain an introduction to OGM's capabilities in assessing genomic integrity List the key takeaways from the webinar and include examples of what the attendee will gain by attending the webinar. For example, what they will learn or how this will benefit their research • Hear how OGM can be applied at various stages of CGT development • Learn from insightful case studies showcasing OGM's impact in CGT research and development Owen Pearce PhD Genomic Engineering Research Associate eGenesis Dr. Michael Gallagher Market Development Manager Bionano